Posted by Michael Wonder on 28 Nov 2022
Croma Australia, a subsidiary of Hugel Aesthetics, receives TGA approval in Australia for Letybo (letibotulinumtoxinA) for the treatment of glabellar lines
28 November 2022 - Approval is supported by positive results from three completed Phase 3 trials that enrolled more than 1000 subjects in the US and Europe.
Hugel America today announced it received TGA approval for Letybo (letibotulinumtoxinA) to treat moderate to severe glabellar (frown) lines in adults.
